The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.
Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge
Study Type
OBSERVATIONAL
Enrollment
102
Oral intake of 75 g glucose after overnight fast
University Hospital Basel, Division of Gastroenterology and Hepatology
Basel, Switzerland
Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT
The difference in GLP-1 secretion in response to oGTT as assessed by area under the curve (AUC) and peak plasma concentration (cmax) in patients with NAFLD compared to healthy controls.
Time frame: 0, 15, 30, 60, 90, 120 min. after glucose administration
Insulin secretion and glucose curves in response to oGTT
Time frame: 0, 15, 30, 60, 90, 120 min. after glucose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.